Rébillard Xavier, Tretarre Brigitte
Service d'urologie, clinique Beau-Soleil, 34070 Montpellier.
Rev Prat. 2007 Mar 31;57(6):595-602.
Estimates of cancer incidence and mortality in France as well as survival data are published by the cancer registry network (Francim). In 2000, the number of new cancer cases was almost 280,000 in France. This number has been gradually increasing, partly due to population aging. The proportion of urological cancers is increasing as well, as a consequence of the marked increase in number of prostate cancers. The estimated number of new cases for the 4 main urological cancers in 2000 reached 61,174, distributed as follows: 40,310 prostate cancers, 10,771 bladder cancers, 8,293 kidney cancers and 1,800 testis cancers. Urological tumours represented at the time 22% of new cancer cases in France: 35% of male cancers (56,402 /161,025) and 4% of female cancers (4,772/117,228). The relative five-year survival for prostate cancers is high: 80%. It is below that of testis cancers (95% after 5 years), but higher than that of kidney cancers (64% in men and 63% in women after five years). Of all urological cancers, bladder cancers have the worst prognosis, since the relative five-year survival is 60% in men and especially 50% in women.
法国癌症登记网络（Francim）发布了法国癌症发病率、死亡率估计数据以及生存数据。2000年，法国新增癌症病例数近28万。这一数字一直在逐渐上升，部分原因是人口老龄化。由于前列腺癌数量显著增加，泌尿系统癌症的比例也在上升。2000年，4种主要泌尿系统癌症的新增病例估计数达到61174例，分布如下：前列腺癌40310例，膀胱癌10771例，肾癌8293例，睾丸癌1800例。当时，泌尿系统肿瘤占法国新增癌症病例的22%：占男性癌症的35%（56402/161025），占女性癌症的4%（4772/117228）。前列腺癌的相对五年生存率较高：为80%。它低于睾丸癌（5年后为95%），但高于肾癌（男性5年后为64%，女性为63%）。在所有泌尿系统癌症中，膀胱癌的预后最差，因为男性的相对五年生存率为60%，女性尤其为50%。
